Retatrutide Predicted Pricing: What Eli Lilly's Triple Agonist Will Cost
Retatrutide is projected to launch at $1,000-$1,500/mo WAC in late 2027. We break down the pricing signals, market forces, and what patients can expect to pay.
Eli Lilly's retatrutide is the most anticipated drug in the GLP-1 pipeline. As a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, it has delivered 28.7% average weight loss at 68 weeks in Phase III trials — roughly 30% more than tirzepatide and 70% more than semaglutide. Seven Phase III TRIUMPH trials are expected to report in 2026, with an FDA submission likely in late 2026 or early 2027 and approval projected for late 2027.
Retatrutide is not yet FDA-approved and has no official price. But based on Lilly's pricing strategy with Mounjaro/Zepbound, the current GLP-1 market dynamics, and analyst projections, we can build a realistic picture of what patients will pay. The short version: expect a $1,000–$1,500/mo list price but $299–$449/mo through LillyDirect and $50/mo for Medicare patients — following the same playbook Lilly used for Zepbound.
Important: Retatrutide is investigational. It is only available through clinical trials. Research-grade peptides sold online as "retatrutide" are not FDA-approved, not manufactured to pharmaceutical standards, and carry significant safety risks. This article discusses projected commercial pricing based on market analysis, not current gray-market availability.
Projected Commercial Pricing (Late 2027–2028)
Analyst consensus points to a WAC of $1,000–$1,500/month, with Lilly likely positioning retatrutide at a premium to Zepbound ($1,086/mo) based on superior efficacy. However, the TrumpRx MFN framework and LillyDirect infrastructure mean self-pay prices will be dramatically lower than WAC from day one — unlike Mounjaro's 2022 launch, when self-pay options didn't exist.
| Channel | Price | Source |
|---|---|---|
| Projected WAC (List Price) | $1,000–$1,500/mo | GLP3 Planner |
| Projected LillyDirect Self-Pay | $299–$449/mo | CNBC |
| Projected Medicare (TrumpRx MFN) | $245/mo | White House |
| Projected Medicare Copay | $50/mo | AJMC |
| Projected Savings Card (Insured) | As low as $25/mo | Zepbound.com |
Why Lilly Will Price at a Premium
Retatrutide's triple-agonist mechanism delivers meaningfully better outcomes than any currently approved GLP-1. Lilly has strong incentive to price above Zepbound to establish retatrutide as the premium tier while keeping Zepbound/Foundayo as the volume play. Revenue projections of $30 billion by 2031 support an aggressive pricing strategy.
| Channel | Price | Source |
|---|---|---|
| Retatrutide Efficacy (Phase III) | 28.7% weight loss | Eli Lilly IR |
| Tirzepatide Efficacy (Comparison) | ~22% weight loss | NEJM |
| Semaglutide Efficacy (Comparison) | ~17% weight loss | NEJM |
| Projected Revenue (2031) | $30B/year | PharmExec |
Why Lilly Can't Price Too High
Several forces constrain retatrutide's pricing ceiling. The TrumpRx MFN commitment caps Medicare at $245/mo regardless of WAC. LillyDirect infrastructure means self-pay patients expect sub-$500 pricing from day one. And the crowded GLP-1 market — with Foundayo, Zepbound, oral Wegovy, and survodutide all competing — limits how much premium the market will bear.
| Channel | Price | Source |
|---|---|---|
| Zepbound Current WAC | $1,086/mo | Lilly Pricing Info |
| Zepbound LillyDirect (Ceiling Reference) | $299–$449/mo | CNBC |
| Foundayo WAC (Oral Competitor) | $649/mo | GoodRx |
| TrumpRx MFN Cap (Medicare) | $245/mo | White House |
Current Gray-Market Pricing (Not Recommended)
Retatrutide is available from research peptide vendors and some compounding pharmacies, though it is not FDA-approved for any indication. These products are not manufactured to pharmaceutical standards, are not tested by the FDA, and quality varies significantly. Health Canada seized retatrutide products in its April 2026 enforcement action. We include these prices for awareness only — we do not recommend purchasing unapproved retatrutide.
| Channel | Price | Source |
|---|---|---|
| Research Peptide Vendors | $50–$100/mo | BodySpec |
| Compounding Pharmacies (Telehealth) | $250–$500/mo | PeptideDeck |
FDA Approval Timeline
Retatrutide is currently in Phase III clinical trials across the TRIUMPH program. Seven additional Phase III readouts are expected through 2026. If all trials succeed, Eli Lilly will likely submit a New Drug Application in late 2026 or early 2027, with FDA approval projected for late 2027 and commercial availability in early 2028.
| Channel | Price | Source |
|---|---|---|
| TRIUMPH-4 (First Phase III Result) | Positive | Eli Lilly IR |
| Remaining Phase III Readouts | 7 trials in 2026 | FindHonestCare |
| Projected FDA Submission | Late 2026–Early 2027 | GLP3 Planner |
| Projected FDA Approval | Late 2027 | GetHeally |